1. Home
  2. SWKS vs ABVX Comparison

SWKS vs ABVX Comparison

Compare SWKS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SWKS

Skyworks Solutions Inc.

HOLD

Current Price

$63.65

Market Cap

9.7B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$134.07

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWKS
ABVX
Founded
1962
2013
Country
United States
France
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
9.0B
IPO Year
1968
N/A

Fundamental Metrics

Financial Performance
Metric
SWKS
ABVX
Price
$63.65
$134.07
Analyst Decision
Hold
Strong Buy
Analyst Count
17
12
Target Price
$81.00
$115.83
AVG Volume (30 Days)
2.4M
1.8M
Earning Date
02-04-2026
08-11-2025
Dividend Yield
4.41%
N/A
EPS Growth
N/A
N/A
EPS
3.08
N/A
Revenue
$4,086,900,000.00
$6,231,374.00
Revenue This Year
N/A
$6.80
Revenue Next Year
$5.06
N/A
P/E Ratio
$20.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.93
$4.77
52 Week High
$95.46
$148.83

Technical Indicators

Market Signals
Indicator
SWKS
ABVX
Relative Strength Index (RSI) 36.57 57.38
Support Level $63.67 $139.42
Resistance Level $64.52 $147.00
Average True Range (ATR) 1.34 7.25
MACD -0.07 0.98
Stochastic Oscillator 0.58 63.38

Price Performance

Historical Comparison
SWKS
ABVX

About SWKS Skyworks Solutions Inc.

Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: